Literature DB >> 21104784

Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors.

Janet L Cunningham1, Teresita Díaz de Ståhl, Tobias Sjöblom, Gunnar Westin, Jan P Dumanski, Eva T Janson.   

Abstract

Serotonin producing endocrine carcinoma of small intestine (ileal carcinoid) is a clinically distinct endocrine tumor. It is generally considered as a sporadic disease and its molecular etiology is poorly understood. We report comprehensive clinical and molecular studies of 55 sporadic and familial patients diagnosed with this condition. Nine pedigrees encompassing 23 affected subjects were established, consistent with autosomal dominant mode of inheritance. Familial and sporadic patients demonstrated indistinguishable clinical pictures. Molecular analyses of 61 tumors from 45 individuals, including eight familial and 37 sporadic patients, aimed at determination of global copy number aberrations using BAC and Illumina SNP arrays and gene expression profiling by Affymetrix chips. Chromosome 18 aberrations were identified in both sporadic and in familial tumors; 100% vs. 38%, respectively. Other, less frequent aberrations were also common for both groups. Global expression profiles revealed no differentially expressed genes. Frequent gain of chromosome 7 was exclusively observed in metastases, when patient matched primary tumors and metastases were compared. Notably, the latter aberration correlated with solid growth pattern morphology (P < 0.01), a histopathological feature that has previously been related to worse prognosis. The clinical and molecular similarities identified between sporadic and familial cases suggest a common pathogenetic mechanism involved in tumor initiation. The familial variant of ileal carcinoid represents a previously unrecognized autosomal dominant inherited tumor disease, which we propose to call Familial Ileal Endocrine Carcinoma (FIEC). Our findings indicate the location of a FIEC tumor suppressor gene near the telomere of 18q, involved in development of inherited and sporadic tumors.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21104784     DOI: 10.1002/gcc.20834

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  32 in total

Review 1.  Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.

Authors:  Sylvia L Asa; Stefano La Rosa; Olca Basturk; Volkan Adsay; Marianna Minnetti; Ashley B Grossman
Journal:  Endocr Pathol       Date:  2021-01-18       Impact factor: 3.943

Review 2.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

3.  Overrepresentation of HLA-DQ2 in small intestinal neuroendocrine tumor patients.

Authors:  Kalle Landerholm; Ursula Falkmer; Roland Persson; Najme Wall; Claes Hallert; Johannes Järhult
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 4.  The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Fabiola Amair-Pinedo; Ignacio Matos; Tamara Saurí; Jorge Hernando; Jaume Capdevila
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

5.  Outcome of surgery for ileojejunal neuroendocrine tumors.

Authors:  Nils Habbe; Volker Fendrich; Anna Heverhagen; Annette Ramaswamy; Detlef K Bartsch
Journal:  Surg Today       Date:  2012-11-11       Impact factor: 2.549

6.  Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection.

Authors:  Christina L Roland; Lee F Starker; Y Kang; Deyali Chatterjee; Jeannelyn Estrella; Asif Rashid; Matthew H Katz; Thomas A Aloia; Jeffrey E Lee; Arvind Dasari; James C Yao; Jason B Fleming
Journal:  Surgery       Date:  2016-11-03       Impact factor: 3.982

Review 7.  Neuroendocrine neoplasms of the gut and pancreas: new insights.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2011-08-02       Impact factor: 43.330

Review 8.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

9.  Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study.

Authors:  Yeting Du; Monica Ter-Minassian; Lauren Brais; Nichole Brooks; Amanda Waldron; Jennifer A Chan; Xihong Lin; Peter Kraft; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2016-08       Impact factor: 5.678

10.  The genomic landscape of small intestine neuroendocrine tumors.

Authors:  Michaela S Banck; Rahul Kanwar; Amit A Kulkarni; Ganesh K Boora; Franziska Metge; Benjamin R Kipp; Lizhi Zhang; Erik C Thorland; Kay T Minn; Ramesh Tentu; Bruce W Eckloff; Eric D Wieben; Yanhong Wu; Julie M Cunningham; David M Nagorney; Judith A Gilbert; Matthew M Ames; Andreas S Beutler
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.